Clinical Trials Logo

Spondylitis, Ankylosing clinical trials

View clinical trials related to Spondylitis, Ankylosing.

Filter by:

NCT ID: NCT05051943 Completed - Clinical trials for Rheumatoid Arthritis

A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

OPALE
Start date: September 29, 2020
Phase:
Study type: Observational

The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.

NCT ID: NCT05038189 Recruiting - Clinical trials for Ankylosing Spondylitis

Evaluation of Spine Posture, Trunk Position Sense and Gait in Axial Spondyloarthritis Patients

Start date: July 15, 2021
Phase: N/A
Study type: Interventional

Axial Spondyloarthritis (Ax-SpA) are chronic systemic inflammatory rheumatological diseases characterized by axial skeletal involvement and enthesitis. Sacroiliitis is the most prominent sign of the disease. The International Society for the Evaluation of Spondyloarthritis created a new classification for Ax-SpA in 2009. According to this classification, Ax-SpA; It is divided into two groups as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). With the emergence of the term nr-axSpA, studies have begun to compare AS and nr-axSpA in terms of genetic, epidemiological and clinical features, treatment needs and response to treatment.However, more studies are needed to better understand the clinical features and symptoms of nr-axSpA patients. The aim of this study was to determine the clinical features of patients with nr-axSpA and AS; To evaluate spine posture, trunk position sense and gait parameters, and also to compare these results with healthy individuals.

NCT ID: NCT04947579 Terminated - Clinical trials for Spondylitis, Ankylosing

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

AS SpA axSpA
Start date: August 25, 2021
Phase: Phase 2
Study type: Interventional

This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.

NCT ID: NCT04943237 Completed - Clinical trials for Ankylosing Spondylitis

Anti-TNF Therapy and Nerve Conduction Studies in Ankylosing Spondylitis

Start date: July 1, 2019
Phase:
Study type: Observational

Patients with ankylosing spondylitis were divided into 2 groups as anti-TNF and conventional therapy according to the treatments they were using for the last 5 years. Nerve conduction studies in the upper and lower extremities of the patients were compared.

NCT ID: NCT04934059 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).

Start date: July 1, 2021
Phase: Phase 4
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Yuxuebi tablet in treating night pain of Ankylosing Spondylitis.

NCT ID: NCT04924270 Recruiting - Clinical trials for Rheumatoid Arthritis

Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases

FRONT
Start date: December 13, 2023
Phase: Phase 2
Study type: Interventional

PURPOSE: The main purpose is to explore clinical efficacy and safety associated with capsule FMT (cFMT) performed in newly diagnosed, untreated patients with rheumatic and gastrointestinal chronic inflammatory diseases (CIDs). DESIGN AND METHODS: In this 1:1 double-blind, placebo-controlled, randomised, 12-month exploratory trial, 200 patients with at least one of 6 different diagnoses of CIDs fulfilling the study criteria will be enrolled at time of diagnosis. The patient groups are: rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), pulmonary sarcoidosis (PSar), Crohn's disease (CD), and ulcerative colitis (UC). The primary endpoint is change from baseline to eight weeks in the physical component summary (PCS) of the short form health survey (SF-36). Key secondary clinical endpoints will be evaluated at 8 weeks. Other secondary clinical endpoints will be evaluated at 52 weeks and reported in secondary papers. The baseline visit will be performed as quickly as possible after the patient's informed consent has been obtained to ensure no unnecessary treatment delay. Stratified by CID diagnosis, patients will be randomised (1:1) to either placebo or single-donor cFMT processed from stool provided to the hospital from anonymous-to-the-patient healthy donors. The experimental intervention FMT/placebo will be repeated once weekly the first month (i.e., each patient will receive a total of four treatments). In addition, all participants will concomitantly be offered the national guideline first-line anti-inflammatory treatment following the baseline visit. At baseline, 8 weeks, 26 weeks, and 52 weeks a thorough clinical examination will be conducted and all relevant clinical scores for each disease entity will be registered. Patient-reported-outcomes including SF-36 and disease specific questionnaires will be collected at week 1, 2, 3, 4, 8 (primary endpoint evaluation), 26 and 52. Adverse events will be monitored through out the trial.

NCT ID: NCT04885751 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy

CEERS
Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy of eupatilin on the prevention of gastroenteropathy in patients with NSAIDs and low dose steroid by comparing with rebamipide.

NCT ID: NCT04876781 Recruiting - Clinical trials for Active Psoriatic Arthritis

Korean Post-marketing Surveillance for Xeljanz XR

XRPMS
Start date: January 12, 2022
Phase:
Study type: Observational

Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea. As part of additional pharmacovigilance activity, this Post-marketing Surveillance (PMS) was planned to evaluate safety and effectiveness of Xeljanz XR under routine clinical practice. At least 200 patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis who were treated with Xeljanz XR will be enrolled about four years.

NCT ID: NCT04875299 Not yet recruiting - Clinical trials for Ankylosing Spondylitis

Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients

Start date: September 2021
Phase:
Study type: Observational

The optimal plasma concentration range of adalimumab in Chinese patients with active ankylosing spondylitis remains unknown, the aims of this study is to determine the concentration-effect relationship, and explore the effect of anti-drug antibody or biomarkers on clinical outcomes in a real-world setting.

NCT ID: NCT04867148 Active, not recruiting - Clinical trials for Ankylosing Spondylitis

The Prediction and Prevention of Disease by Using Big Data in Motion Analysis

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Variable patterns of gait disturbance can be found in patients with spine disease including the problems of gait initiation, freezing of gait, reduced balance and postural control, reduced step lengths, increased step times, and slow walking speed.